Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc. (KRTX): 3 pipeline candidates · ~14 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
14.2 months
D/E 0.07 · 0% dilution
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for Karuna Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$185.8M
Quarterly Burn
$111.1M
Runway
14.2 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| kar-2618 | Preclinical |
| karxt | Phase 3 |
| xanomeline | Phase 3 |
Frequently asked questions
How many drug candidates are in Karuna Therapeutics, Inc.'s pipeline?
Karuna Therapeutics, Inc. (KRTX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Karuna Therapeutics, Inc.'s lead drug candidate?
Karuna Therapeutics, Inc.'s most advanced tracked candidate is kar-2618 (Preclinical) for mood and anxiety disorders.
What is Karuna Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Karuna Therapeutics, Inc. has approximately 14.2 months of cash runway.
Who is the CEO of Karuna Therapeutics, Inc.?
Bill Meury is the chief executive officer of Karuna Therapeutics, Inc. (KRTX).
Get the full picture on Karuna Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.